Skip to content

A study on relapse of the symptom comparing 2 weeks and 8 weeks of treatment period in GERD patients using the newly established GerdQ questionnaires

A study on relapse of the symptom comparing 2 weeks and 8 weeks of treatment period in GERD patients using the newly established GerdQ questionnaires - GERD treatment period study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008551
Enrollment
80
Registered
2012-07-30
Start date
2012-07-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD

Interventions

no additional treatment Additional treatment of esomeprazole for 6 weeks

Sponsors

Tokai University School of Medicine
Lead Sponsor
Showa University Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: LA grade A or B diagnosed by esophagoscopy within 6 months Having GER symptoms Disappearance of GER symptoms after the treatment by esomeprazole (20 mg/day for 2 weeks) by GerdQ questionnaire

Exclusion criteria

Exclusion criteria: Patiets with the history of gastric surgeries Patients with alarm symptoms such as vomiting, GI bleeding, rapid body weight loss Patients of alcohol or drug dependence Patients with severe endocrine problems Patients with severe injuries of heart, liver, kidney or bone marrow functions Patients with allergy against the test drugs Patients with pregnancy, possible pregnancy or breast feeding, or hope of pregnancy during the test period Patients whom the doctor decide as not proper for the study

Design outcomes

Primary

MeasureTime frame
length of the GER symptom free periods after the treatment

Secondary

MeasureTime frame
1) factors affecting the relapse of GERD 2) difference of GER symptoms between before and after the 2 week treatment and the rates of the disappearance of GER symptoms 3) the severity of GER symptoms in case of the relapse

Countries

Japan

Contacts

Public ContactMasashi Matsushima

Tokai University Tokyo Hospital Internal Medicine (Gastroenterology)

03-3370-2321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026